7 results found.

Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or P Clinical Trial using Momelotinib; Ruxolitinib; Placebo to match momelotinib; Placebo to match ruxolitinib

Gilead Sciences - Recruiting 18 years or older.
- A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).
Momelotinib; Ruxolitinib; Placebo to match momelotinib; Placebo to match ruxolitinib

Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibros Clinical Trial using Ruxolitinib (INCB018424)

Incyte Corporation - Recruiting 18 years or older.
- An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis (PPV-MF) and Post Polycythemia Vera-myelofibrosis (PET-MF) Who Have Platelet Counts of 50 x 10^9/L to 100 x 10^9/L.
Ruxolitinib (INCB018424)

Myelofibrosis Clinical Trial using Ruxolitinib

Incyte Corporation - Recruiting 18 years or older.
- .
Ruxolitinib

Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or P Clinical Trial using Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)

Mount Sinai School of Medicine - Recruiting 18 years to 70 years.
- Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) With Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis.
Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)

Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or P Clinical Trial using PRM-151; Ruxolitinib

Promedior, Inc. - Recruiting 18 years or older.
- A Phase 2, Open-Label, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), Or Post-Essential Thrombocythemia MF (Post-ET MF).
PRM-151; Ruxolitinib

Primary Myelofibrosis, Post-Polycythemic Vera Myelofibrosis, or P Clinical Trial using NS-018

NS Pharma, Inc. - Recruiting 18 years or older.
- A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF.
NS-018

Primary Myelofibrosis, Secondary Myelofibrosis, PMF, SMF, Post-PV Clinical Trial using INCB018424/CC-4047

University of Ulm - Recruiting 18 years or older.
- A Phase-Ib/II Study of Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary Myelofibrosis.
INCB018424/CC-4047